1029 related articles for article (PubMed ID: 16636531)
21. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
22. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of efficacy of darbepoetin alfa administered once monthly as treatment of anemia in predialysis patients with chronic kidney disease].
Martínez PM; García de Vinuesa S; Ortega Díaz M; Goicoechea M; Gómez Campderá F; Luño J
Nefrologia; 2005; 25(6):663-7. PubMed ID: 16514907
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
Fang YW; Chang CH
Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
[TBL] [Abstract][Full Text] [Related]
25. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
[TBL] [Abstract][Full Text] [Related]
26. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
27. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R
Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149
[TBL] [Abstract][Full Text] [Related]
28. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
29. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
30. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
[TBL] [Abstract][Full Text] [Related]
31. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
32. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
33. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
[TBL] [Abstract][Full Text] [Related]
34. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.
Ling B; Walczyk M; Agarwal A; Carroll W; Liu W; Brenner R
Clin Nephrol; 2005 May; 63(5):327-34. PubMed ID: 15909591
[TBL] [Abstract][Full Text] [Related]
35. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
Silver MR; Agarwal A; Krause M; Lei L; Stehman-Breen C
Am J Geriatr Pharmacother; 2008 Jun; 6(2):49-60. PubMed ID: 18675764
[TBL] [Abstract][Full Text] [Related]
36. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
[TBL] [Abstract][Full Text] [Related]
38. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa.
Aarup M; Bryndum J; Dieperink H; Joffe P
Nephrol Dial Transplant; 2006 May; 21(5):1312-6. PubMed ID: 16396971
[TBL] [Abstract][Full Text] [Related]
40. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
